Role of Immunotherapies Emerging in Gastric/GEJ Cancers
Andrew Ko, MD, discusses how the approval of pembrolizumab has impacted patients with positive PD-L1 expression and how clinical trials that have reshaped the standard of care in patients with gastric and GEJ cancers.
Source: OncLive